RUNX2 and neoplasm: Indeed, Akech et al. [29] indicated that RUNX2 is associated with prostate cancer bone metastasis and maybe a potential therapeutic target to block prostate cancer cells ability for tumor growth and metastatic lesions formation in vivo.